10 g/kg) or vehicle for 4 hours before tissue collection
Tesofensine operates through a completely different mechanism: it blocks reuptake of dopamine, norepinephrine, and serotonin simultaneously, creating a triple monoamine effect that intensifies with every compound that touches those same pathways
The clinical development program has demonstrated unprecedented efficacy that exceeds any currently available obesity pharmacotherapy
This creates a translational gap, specifically for conditions where current treatment fail to achieve rapid improvements in symptoms (e.g., anhedonia in major depressive disorder
Potential to reduce addiction Although research is in its early stages, there are signs that GLP-1s may be useful in reducing cravings for things other than food
Pope NH, Salmon M, Davis JP, Chatterjee A, Su G, Conte MS, et al